Showing results (181-190 of 214) with videos related to
Sort By:
Pageof 22
Leukemia|October 1, 1996
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adultsS M Kornblau, V Gandhi, H M Andreeff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemiaA Ferrajoli, T Manshouri, Z Estrov, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemiaS Faderl, P F Thall, H M Kantarjian, et al.Blood|March 1, 1993
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemiaH M Kantarjian, M Beran, A Ellis, et al.Cancer|September 15, 1991
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemiaH M Kantarjian, M Talpaz, M J Keating, et al.Leukemia|October 27, 1997
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemiaH M Kantarjian, S M O'Brien, M Keating, et al.Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.Leukemia|March 1, 1996
Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemiaH M Kantarjian, M Beran, S O'Brien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factorH M Kantarjian, M Talpaz, D Kontoyiannis, et al.Experimental Hematology|March 1, 1992
KBM-3, an in vitro model of human acute myelomonocytic leukemiaB S Andersson, U S Bergerheim, V P Collins, et al.Pageof 22